{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:52:29Z","timestamp":1789167149836,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients receiving chemotherapy for cancer treatment may develop chemotherapy-induced peripheral neuropathy (CIPN), a type of neuropathic (nerve) pain that is often difficult to treat. First-line analgesic\/adjuvant agents recommended for the treatment of neuropathic pain often lack efficacy and\/or evoke dose-limiting side-effects in patients with CIPN. Hence, there is a large unmet medical need for novel, well-tolerated analgesics for improving the relief of CIPN. As NLRP3 inflammasome activation is implicated in the pathobiology of CIPN, our aim was to assess the pain relief efficacy of a small molecule NLRP3 inflammasome inhibitor (MCC950), for the relief of CIPN in a rat model. Sprague\u2013Dawley rats received four doses of cisplatin at once-weekly intervals. Temporal development of mechanical allodynia was documented in the bilateral hindpaws using von Frey filaments over a 4-week period after the first cisplatin dose. Rats with fully developed mechanical allodynia in the hindpaws received single oral doses of MCC950 (10\u2013300\u00a0mg\/kg), pregabalin (30\u00a0mg\/kg) or vehicle. Hindpaw withdrawal thresholds were assessed pre-dose and at multiple times over a 4\u00a0h post-dosing period to produce PWT versus time curves. Single doses of MCC950 evoked dose-dependent anti-allodynia in the hindpaws, with the peak effect observed at 2\u20133\u00a0h post-dose. The mean effective dose 50% (ED\n                    <jats:sub>50<\/jats:sub>\n                    ; 95% confidence intervals) of MCC950 was 56.2\u00a0mg\/kg (21.8\u2013150.7\u00a0mg\/kg). On a molar basis, oral pregabalin was\u2009~\u200920% more potent than MCC950 in this model. In conclusion, NLRP3 inflammasome inhibitors are worthy of further investigation as novel treatments for CIPN.\n                  <\/jats:p>","DOI":"10.1007\/s10787-026-02360-w","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:44Z","timestamp":1786369064000},"page":"6109-6118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An NLRP3 inflammasome inhibitor evoked dose-dependent anti-allodynia in the hindpaws of a rat model of chemotherapy-induced peripheral neuropathy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1287-5051","authenticated-orcid":false,"given":"L. H. C.","family":"Kek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-9781","authenticated-orcid":false,"given":"M. Z.","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4563-1682","authenticated-orcid":false,"given":"O.","family":"Sriwatananukulkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-3114","authenticated-orcid":false,"given":"A.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-3805","authenticated-orcid":false,"given":"K.","family":"Schroder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-3734","authenticated-orcid":false,"given":"M. T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2360_CR1","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","volume":"18","author":"EH Bae","year":"2021","unstructured":"Bae EH, Greenwald MK, Schwartz AG (2021) Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics 18:2384\u20132396. https:\/\/doi.org\/10.1007\/s13311-021-01142-2","journal-title":"Neurotherapeutics"},{"key":"2360_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s10787-023-01235-8","volume":"31","author":"C Chen","year":"2023","unstructured":"Chen C, Smith MT (2023) The NLRP3 inflammasome: role in the pathobiology of chronic pain. Inflammopharmacology 31:1589\u20131603. https:\/\/doi.org\/10.1007\/s10787-023-01235-8","journal-title":"Inflammopharmacology"},{"key":"2360_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"KP Chen","year":"2022","unstructured":"Chen KP, Hua KF, Tsai FT, Lin TY, Cheng CY, Yang DI, Hsu HT, Ju TC (2022a) A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington\u2019s disease. J Neuroinflammation 19:56. https:\/\/doi.org\/10.1186\/s12974-022-02419-9","journal-title":"J Neuroinflammation"},{"key":"2360_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02669-7","volume":"19","author":"W Chen","year":"2022","unstructured":"Chen W, Wang X, Sun Q, Zhang Y, Liu J, Hu T, Wu W, Wei C, Liu M, Ding Y, Liu D, Chong Y, Wang P, Zhu H, Cui W, Zhang J, Li Q, Yang F (2022b) The upregulation of NLRP3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (TET2) contributed to diabetic neuropathic pain in mice. J Neuroinflammation 19:302. https:\/\/doi.org\/10.1186\/s12974-022-02669-7","journal-title":"J Neuroinflammation"},{"key":"2360_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41577-024-01075-9","volume":"25","author":"RC Coll","year":"2025","unstructured":"Coll RC, Schroder K (2025) Inflammasome components as new therapeutic targets in inflammatory disease. Nat Rev Immunol 25:22\u201341. https:\/\/doi.org\/10.1038\/s41577-024-01075-9","journal-title":"Nat Rev Immunol"},{"key":"2360_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Nunez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O\u2019Neill LA (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248\u2013255. https:\/\/doi.org\/10.1038\/nm.3806","journal-title":"Nat Med"},{"key":"2360_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB, Schroder K (2019) MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15:556\u2013559. https:\/\/doi.org\/10.1038\/s41589-019-0277-7","journal-title":"Nat Chem Biol"},{"issue":"Suppl 1","key":"2360_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","volume":"160","author":"LA Colvin","year":"2019","unstructured":"Colvin LA (2019) Chemotherapy-induced peripheral neuropathy: where are we now? Pain 160(Suppl 1):S1\u2013S10. https:\/\/doi.org\/10.1097\/j.pain.0000000000001540","journal-title":"Pain"},{"key":"2360_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137227","author":"IK Domingo","year":"2022","unstructured":"Domingo IK, Latif A, Bhavsar AP (2022) Pro-inflammatory signalling PRRopels cisplatin-induced toxicity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23137227","journal-title":"Int J Mol Sci"},{"key":"2360_CR10","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00520-019-05063-x","volume":"28","author":"JS Gewandter","year":"2020","unstructured":"Gewandter JS, Kleckner AS, Marshall JH, Brown JS, Curtis LH, Bautista J, Dworkin RH, Kleckner IR, Kolb N, Mohile SG, Mustian KM (2020) Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer 28:2553\u20132562. https:\/\/doi.org\/10.1007\/s00520-019-05063-x","journal-title":"Support Care Cancer"},{"key":"2360_CR11","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1007\/s12035-016-0273-9","volume":"54","author":"MF Gorgun","year":"2017","unstructured":"Gorgun MF, Zhuo M, Englander EW (2017) Cisplatin toxicity in dorsal root ganglion neurons is relieved by meclizine via diminution of mitochondrial compromise and improved clearance of DNA damage. Mol Neurobiol 54:7883\u20137895. https:\/\/doi.org\/10.1007\/s12035-016-0273-9","journal-title":"Mol Neurobiol"},{"key":"2360_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00156","volume":"4","author":"Y Han","year":"2013","unstructured":"Han Y, Smith MT (2013) Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 4:156. https:\/\/doi.org\/10.3389\/fphar.2013.00156","journal-title":"Front Pharmacol"},{"key":"2360_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/FBP.0000000000000090","volume":"25","author":"FY Han","year":"2014","unstructured":"Han FY, Wyse BD, Smith MT (2014) Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. Behav Pharmacol 25:732\u2013740. https:\/\/doi.org\/10.1097\/FBP.0000000000000090","journal-title":"Behav Pharmacol"},{"key":"2360_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, Hara H, Nunez G (2016) Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 41:1012\u20131021. https:\/\/doi.org\/10.1016\/j.tibs.2016.09.002","journal-title":"Trends Biochem Sci"},{"key":"2360_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/1744806917719804","volume":"13","author":"M Jia","year":"2017","unstructured":"Jia M, Wu C, Gao F, Xiang H, Sun N, Peng P, Li J, Yuan X, Li H, Meng X, Tian B, Shi J, Li M (2017) Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain. Mol Pain 13:1744806917719804. https:\/\/doi.org\/10.1177\/1744806917719804","journal-title":"Mol Pain"},{"key":"2360_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10787-017-0401-9","volume":"26","author":"N Khan","year":"2018","unstructured":"Khan N, Kuo A, Brockman DA, Cooper MA, Smith MT (2018) Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology 26:77\u201386. https:\/\/doi.org\/10.1007\/s10787-017-0401-9","journal-title":"Inflammopharmacology"},{"key":"2360_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/JPR.S506569","volume":"18","author":"W Kui","year":"2025","unstructured":"Kui W, Li Y, Gu Z, Xie L, Huang A, Kong S, Song L, Li L, Yu J, Xue CC, Wang K (2025) Electroacupuncture inhibits NLRP3-mediated microglial pyroptosis to ameliorate chronic neuropathic pain in rats. J Pain Res 18:1115\u20131129. https:\/\/doi.org\/10.2147\/JPR.S506569","journal-title":"J Pain Res"},{"key":"2360_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070940","author":"A Kuo","year":"2021","unstructured":"Kuo A, Corradini L, Nicholson JR, Smith MT (2021) Assessment of the anti-allodynic and anti-hyperalgesic efficacy of a glycine transporter 2 inhibitor relative to pregabalin, duloxetine and indomethacin in a rat model of cisplatin-induced peripheral neuropathy. Biomolecules. https:\/\/doi.org\/10.3390\/biom11070940","journal-title":"Biomolecules"},{"key":"2360_CR19","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","volume":"29","author":"C Maihofner","year":"2021","unstructured":"Maihofner C, Diel I, Tesch H, Quandel T, Baron R (2021) Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer 29:4223\u20134238. https:\/\/doi.org\/10.1007\/s00520-021-06042-x","journal-title":"Support Care Cancer"},{"key":"2360_CR20","doi-asserted-by":"publisher","first-page":"FF11","DOI":"10.7860\/JCDR\/2015\/13373.5955","volume":"9","author":"A Mangaiarkkarasi","year":"2015","unstructured":"Mangaiarkkarasi A, Rameshkannan S, Ali RM (2015) Effect of gabapentin and Pregabalin in rat model of Taxol induced neuropathic pain. J Clin Diagn Res 9:FF11-14. https:\/\/doi.org\/10.7860\/JCDR\/2015\/13373.5955","journal-title":"J Clin Diagn Res"},{"key":"2360_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14020143","author":"I Martinez-Martel","year":"2025","unstructured":"Martinez-Martel I, Negrini-Ferrari SE, Pol O (2025) MCC950 reduces the anxiodepressive-like behaviors and memory deficits related to paclitaxel-induced peripheral neuropathy in mice. Antioxidants. https:\/\/doi.org\/10.3390\/antiox14020143","journal-title":"Antioxidants"},{"issue":"565\u2013590","key":"2360_CR22","doi-asserted-by":"publisher","first-page":"vi","DOI":"10.1016\/s1094-9194(17)30111-1","volume":"2","author":"DE McClure","year":"1999","unstructured":"McClure DE (1999) Clinical pathology and sample collection in the laboratory rodent. Vet Clin North Am Exot Anim Pract 2(565\u2013590):vi. https:\/\/doi.org\/10.1016\/s1094-9194(17)30111-1","journal-title":"Vet Clin North Am Exot Anim Pract"},{"key":"2360_CR23","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/JPR.S383981","volume":"15","author":"K Nozawa","year":"2022","unstructured":"Nozawa K, Karasawa Y, Shidahara Y, Ushida T (2022) Efficacy of combination therapy with pregabalin in neuropathic pain: a preclinical study in the rat L5 spinal nerve ligation model. J Pain Res 15:3469\u20133478. https:\/\/doi.org\/10.2147\/JPR.S383981","journal-title":"J Pain Res"},{"key":"2360_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/SHK.0000000000001832","volume":"56","author":"C Ren","year":"2021","unstructured":"Ren C, Chen M, Mu G, Peng S, Liu X, Ou C (2021) NLRP3 inflammasome mediates neurodegeneration in rats with chronic neuropathic pain. Shock 56:840\u2013849. https:\/\/doi.org\/10.1097\/SHK.0000000000001832","journal-title":"Shock"},{"key":"2360_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461\u20132470. https:\/\/doi.org\/10.1016\/j.pain.2014.09.020","journal-title":"Pain"},{"key":"2360_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12974-023-02765-2","volume":"20","author":"ZM Shi","year":"2023","unstructured":"Shi ZM, Jing JJ, Xue ZJ, Chen WJ, Tang YB, Chen DJ, Qi XY, Huang L, Zou YQ, Wu XZ, Yang F (2023) Stellate ganglion block ameliorated central post-stroke pain with comorbid anxiety and depression through inhibiting HIF-1alpha\/NLRP3 signaling following thalamic hemorrhagic stroke. J Neuroinflammation 20:82. https:\/\/doi.org\/10.1186\/s12974-023-02765-2","journal-title":"J Neuroinflammation"},{"key":"2360_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad022","volume":"3","author":"P Silva Santos Ribeiro","year":"2023","unstructured":"Silva Santos Ribeiro P, Willemen H, Versteeg S, Martin Gil C, Eijkelkamp N (2023) NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain. Immunother Adv 3:ltad022. https:\/\/doi.org\/10.1093\/immadv\/ltad022","journal-title":"Immunother Adv"},{"key":"2360_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, de Andrade DC, Baron R, Belton J, Bennett DLH, Calvo M, Dougherty P, Gilron I, Hietaharju AJ, Hosomi K, Kamerman PR, Kemp H, Enax-Krumova EK, McNicol E, Price TJ, Raja SN, Rice ASC, Smith BH, Talkington F, Truini A, Vollert J, Attal N, Finnerup NB, Haroutounian S, Neu PRUSG (2025) Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol 24:413\u2013428. https:\/\/doi.org\/10.1016\/S1474-4422(25)00068-7","journal-title":"Lancet Neurol"},{"key":"2360_CR29","doi-asserted-by":"publisher","first-page":"e20201452","DOI":"10.1084\/jem.20201452","volume":"218","author":"H Starobova","year":"2021","unstructured":"Starobova H, Monteleone M, Adolphe C, Batoon L, Sandrock CJ, Tay B, Deuis JR, Smith AV, Mueller A, Nadar EI, Lawrence GP, Mayor A, Tolson E, Levesque JP, Pettit AR, Wainwright BJ, Schroder K, Vetter I (2021) Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1beta release. J Exp Med 218:e20201452. https:\/\/doi.org\/10.1084\/jem.20201452","journal-title":"J Exp Med"},{"key":"2360_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70092","volume":"9","author":"H Starobova","year":"2025","unstructured":"Starobova H, McCalmont H, Shatunova S, Tay N, Smith CM, Robertson A, Winkler I, Lock RB, Vetter I (2025) Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine-induced adverse effects in an acute lymphoblastic leukemia patient-derived xenograft model. Hemasphere 9:e70092. https:\/\/doi.org\/10.1002\/hem3.70092","journal-title":"Hemasphere"},{"key":"2360_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","volume":"15","author":"A Tapia-Abellan","year":"2019","unstructured":"Tapia-Abellan A, Angosto-Bazarra D, Martinez-Banaclocha H, de Torre-Minguela C, Ceron-Carrasco JP, Perez-Sanchez H, Arostegui JI, Pelegrin P (2019) MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol 15:560\u2013564. https:\/\/doi.org\/10.1038\/s41589-019-0278-6","journal-title":"Nat Chem Biol"},{"key":"2360_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/j.pain.0000000000001177","volume":"159","author":"C Wahlman","year":"2018","unstructured":"Wahlman C, Doyle TM, Little JW, Luongo L, Janes K, Chen Z, Esposito E, Tosh DK, Cuzzocrea S, Jacobson KA, Salvemini D (2018) Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. Pain 159:1025\u20131034. https:\/\/doi.org\/10.1097\/j.pain.0000000000001177","journal-title":"Pain"},{"key":"2360_CR33","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1111\/bph.15215","volume":"177","author":"T Zhang","year":"2020","unstructured":"Zhang T, Fang Z, Linghu KG, Liu J, Gan L, Lin L (2020) Small molecule-driven SIRT3-autophagy-mediated NLRP3 inflammasome inhibition ameliorates inflammatory crosstalk between macrophages and adipocytes. Br J Pharmacol 177:4645\u20134665. https:\/\/doi.org\/10.1111\/bph.15215","journal-title":"Br J Pharmacol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02360-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:12:23Z","timestamp":1788963143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02360-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02360-w","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kek LHC, Imam MZ and Sriwatananukulkit O have no declarations of interest to disclose. In the past 3-years, Kuo A and Smith MT have collaborated with Boehringer Ingelheim Pharma GmbH & Co. KG on contract-funded collaborative research unrelated to the topic of this research. Schroder K is a co-inventor on patent applications for NLRP3 inhibitors which have been licensed to Inflazome Ltd, acquired by Roche.\u00a0KS served on the Scientific Advisory Boards of Inflazome, and Quench Bio, USA and Novartis, Switzerland.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}